These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21323535)

  • 1. Development of novel combination therapies.
    Woodcock J; Griffin JP; Behrman RE
    N Engl J Med; 2011 Mar; 364(11):985-7. PubMed ID: 21323535
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 3. Improving the FDA's advisory committee process.
    Brass EP; Hiatt WR
    J Clin Pharmacol; 2012 Aug; 52(8):1277-83. PubMed ID: 21908879
    [No Abstract]   [Full Text] [Related]  

  • 4. Breakthrough drug category demands more communication.
    Carroll J
    Manag Care; 2013 Aug; 22(8):17-8. PubMed ID: 24024248
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory watch: FDA guidance on co-developing investigational drugs.
    Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
    [No Abstract]   [Full Text] [Related]  

  • 7. US regulation of combination products.
    Donawa M
    Med Device Technol; 2009 Oct; 20(6):22, 24-5. PubMed ID: 20302139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incentives for drug development--the curious case of colchicine.
    Kesselheim AS; Solomon DH
    N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164
    [No Abstract]   [Full Text] [Related]  

  • 9. The 21st Century Cures Act--Will It Take Us Back in Time?
    Avorn J; Kesselheim AS
    N Engl J Med; 2015 Jun; 372(26):2473-5. PubMed ID: 26039522
    [No Abstract]   [Full Text] [Related]  

  • 10. Competitors try collaboration to speed drug development.
    Patlak M
    J Natl Cancer Inst; 2010 Jun; 102(12):841-3. PubMed ID: 20530762
    [No Abstract]   [Full Text] [Related]  

  • 11. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2013; 29(6):513-4. PubMed ID: 23841863
    [No Abstract]   [Full Text] [Related]  

  • 12. Translation of cancer immunotherapies.
    Mulé JJ; Weber JS
    Nat Med; 2004 Nov; 10(11):1153; author reply 1153-4. PubMed ID: 15516900
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory innovation and drug development for early-stage Alzheimer's disease.
    Kozauer N; Katz R
    N Engl J Med; 2013 Mar; 368(13):1169-71. PubMed ID: 23484795
    [No Abstract]   [Full Text] [Related]  

  • 14. 2013 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA regulations for drug development.
    Behrman RE; Woodcock J
    Science; 2010 Jul; 329(5987):33; author reply 33. PubMed ID: 20595600
    [No Abstract]   [Full Text] [Related]  

  • 16. Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.
    Vaduganathan M; Butler J; Gheorghiade M
    Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27707750
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.
    Miller KL; Lanthier M
    Nat Rev Drug Discov; 2015 Feb; 14(2):83. PubMed ID: 25633785
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of public-sector research in the discovery of drugs and vaccines.
    Stevens AJ; Jensen JJ; Wyller K; Kilgore PC; Chatterjee S; Rohrbaugh ML
    N Engl J Med; 2011 Feb; 364(6):535-41. PubMed ID: 21306239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bracing for the biosimilar wave.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(3):152-154. PubMed ID: 28248938
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.